COMP <GO>
LH vs LLY // REVENUE GROWTH (YOY)
Labcorp Holdings Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: LH 4
— LLY 11
▲ REVENUE GROWTH (YOY) LEADER: LLY
LAST: $361.39 (-1.84%) • MKT CAP: $29.86B
revenue-growth
7.20%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 28.80% | 83.64% | -54.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.30% | 32.36% | -24.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.6x | 36.4x | -16.82 | LH | /valuation <GO> |
| Free Cash Flow Yield | 4.04% | 2.30% | +1.74 | LH | /fcf-yield <GO> |
| Operating Margin | 9.90% | 40.21% | -30.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | 6.30% | 31.90% | -25.60 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 7.20% | 45.51% | -38.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.81% | 0.49% | +0.32 | LH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.58 | 9.29 | -5.71 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.77% | +0.03 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 74.5 | 77.9 | -3.34 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.51 | +0.45 | LH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.6x | 26.3x | +5.35 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.86B | $1.33T | -$1.30T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LH REV | LLY REV | LH GROSS % | LLY GROSS % | LH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $13.95B | $65.18B | 28.8% | 83.0% | $1.21B | $16.81B |
| FY 2024 | $13.01B | $45.04B | 27.9% | 81.3% | $1.10B | $8.82B |
| FY 2023 | $12.16B | $34.12B | 44.0% | 79.3% | $780.4M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LH // BETA 0.96
LLY // BETA 0.51